Blue Cross Blue Shield MA Vitamin B12 Coverage

Coverage and Medical Necessity Criteria

inv-01: Vitamin B12 Testing - Medically Necessary Indications

Measurement of Vitamin B12 level is considered MEDICALLY NECESSARY for individuals with ANY of the following indications:

Vitamin B12 indications: Inadequate intake of B12 (malnutrition); eating disorders (e.g., anorexia); alcohol dependence; inadequate dietary intake such as strict vegan diet without supplementation; malabsorption (including blind loop syndrome, achlorhydria, celiac disease); chronic use of H2 receptor antagonist or proton pump inhibitor (minimum of 12 months); disruption of gastrointestinal anatomy or function (e.g., gastrectomy, gastric bypass, ileal resection, gastric cancer, inflammatory bowel disease, Crohn's disease); infections associated with B12 deficiency (bacterial overgrowth, fish tapeworm, Helicobacter infection, HIV); pancreatic insufficiency; malignancy affecting nutrient absorption; pernicious anemia/intrinsic factor deficiency; Whipple's disease; tropical sprue; metabolic causes (disorders of sulfur amino acid metabolism, homocystinuria, MTHFR deficiency); chronic metformin use (minimum of 4 months); symptoms suggesting B12 deficiency including cognitive changes, amnesia, abnormalities of gait/mobility/coordination, neuropathy, diabetes mellitus with neuropathy or neurologic complications, glossitis/glossodynia, failure to thrive (pediatric), anemia or other cytopenias/pancytopenia, macrocytic anemia or macrocytosis with oval or hypersegmented neutrophils, and other neurologic or motor abnormalities.

List captured from policy text

inv-02: MMA Testing - Medically Necessary Indications

Methylmalonic acid (MMA) testing is considered MEDICALLY NECESSARY for ANY of the following indications:

MMA indications: Serum vitamin B12 levels are low or borderline-low; Type 2 diabetes mellitus patients on metformin who have neurologic symptoms; positive newborn screening suggesting organic acidemia (to evaluate for inborn errors of metabolism).

Per policy

inv-03: Holotranscobalamin Testing

Holotranscobalamin stance: Holotranscobalamin testing as a marker for vitamin B12 deficiency is considered INVESTIGATIONAL for all indications.

Per policy

inv-04: Medical necessity criteria for testing

Covered when ALL of the following are met

General coverage requirement: Testing is intended to evaluate suspected vitamin B12 deficiency and is performed for symptomatic individuals or those at high risk for deficiency; routine screening of average-risk asymptomatic adults is not recommended.

See high-risk and symptomatic indications below.

High-risk or symptomatic indications (any): History of inflammatory bowel disease; history of gastric or intestinal resection; prolonged vegan diet without supplementation; long-term use of H2 receptor antagonists or proton pump inhibitors (>=12 months); long-term metformin use (>=4 months); elderly; neurologic or hematologic features suggestive of deficiency (e.g., cognitive changes, gait/mobility disturbance, neuropathy, macrocytic anemia, pancytopenia).

Derived from policy narrative

Confirmatory/adjunct testing: MMA testing is appropriate to confirm deficiency when serum vitamin B12 is normal to low-normal in asymptomatic high-risk individuals; MMA is also appropriate for newborn screening follow-up for inborn errors and for Type II diabetics with peripheral neuropathy. Holotranscobalamin has been studied but there is no consensus to use it routinely in addition to or instead of total serum B12 and it is considered investigational.

Vitamin B12 screening and testing is considered NOT MEDICALLY NECESSARY for all other indications not specifically listed as medically necessary in this policy. The policy lists the clinical and risk-factor indications that justify testing (for example, malabsorption conditions, altered GI anatomy, prolonged medication exposures, neurologic or hematologic signs); tests ordered for indications outside those listed may be denied as not medically necessary.

Routine screening of vitamin B12 in asymptomatic, average-risk adults is not recommended. The policy states there are no guidelines supporting routine testing in asymptomatic adults and notes the Centers for Medicare & Medicaid Services does not provide coverage for routine vitamin B12 testing.

No explicit coverage exclusions beyond those already stated are provided in the available excerpt. The fragment does not list additional tests or specific clinical conditions that are expressly excluded from coverage.

Holotranscobalamin testing is considered INVESTIGATIONAL for all indications and is therefore not covered by this policy. The policy explicitly states holotranscobalamin is investigational as a marker for vitamin B12 deficiency.

The policy reiterates that routine (asymptomatic) vitamin B12 testing lacks guideline support and that CMS does not provide coverage for routine testing. As such, routine population screening is not supported by this policy.

Within the provided excerpt there are no additional conditions explicitly labeled as "not medically necessary" beyond the statements about routine screening and investigational tests; further details would be found in the full policy document.

Detailed Indications for Testing

inv-36: Evaluation of suspected vitamin B12 deficiency per listed clinical indications; MMA testing when B12 low/borderline or specific scenarios (metformin with neurologic symptoms, positive newborn screen).

Covered when ALL of the following are met

Evaluation of suspected deficiency: Order documentation indicates symptomatic presentation or high-risk condition (e.g., IBD, prior gastric or intestinal resection, prolonged vegan diet, long-term PPI/H2 antagonist use >=12 months, metformin use >=4 months, elderly) or other clinical rationale for testing.

Clinical indication required for coverage

Clinical presentations supporting testing: Neurologic signs or symptoms (cognitive changes, amnesia, ataxia, paresthesia, neuropathy, other motor abnormalities); hematologic findings (macrocytic anemia, macrocytosis with oval or hypersegmented neutrophils, pancytopenia, other cytopenias); gastrointestinal risk factors or malabsorption conditions; infections or other causes associated with B12 deficiency.

Per policy list of indications

Use of confirmatory testing when indicated:

Procedure and Diagnosis Codes

Covered CPT Codes (informational listing)CPT

82607

Cyanocobalamin (Vitamin B-12)

ICD-10 Diagnosis Codes (examples listed as medically necessary when criteria met)ICD-10

B20	Human immunodeficiency virus [HIV] disease
B70.0	Diphyllobothriasis
B96.81	Helicobacter pylori
C16.0	Malignant neoplasm of cardia
D51.0	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria

Associated ICD-10 Diagnosis CodesICD-10

K51.019	Ulcerative (chronic) pancolitis with unspecified complications
K51.20	Ulcerative (chronic) proctitis without complications
K51.211	Ulcerative (chronic) proctitis with rectal bleeding
K51.212	Ulcerative (chronic) proctitis with intestinal obstruction
K51.218	Ulcerative (chronic) proctitis with other complication
K51.219	Ulcerative (chronic) proctitis with unspecified complications
K51.30	Ulcerative (chronic) rectosigmoiditis without complications
K51.311	Ulcerative (chronic) rectosigmoiditis with rectal bleeding
K51.313	Ulcerative (chronic) rectosigmoiditis with intestinal obstruction / with fistula
K51.318	Ulcerative (chronic) rectosigmoiditis with other complication

1–10 of 74

1/8

inv-14: Chronic medication duration — Metformin use minimum of 4 months; chronic PPI or H2 blocker use minimum of 1 year

Metformin durationChronic metformin use minimum of 4 months

PPI or H2 blocker durationChronic use of proton pump inhibitors or H2 receptor antagonists minimum of 12 months (minimum of year)

ContextDurations referenced as risk thresholds prompting consideration of B12 testing in high‑risk individuals

inv-15: Duration thresholds for medication risk — Proton pump inhibitors or H2 receptor antagonists >= 12 months; metformin >= 4 months

PPI / H2 antagonist thresholdProton pump inhibitors or H2 receptor antagonists used for >= 12 months

Prior Authorization, Documentation, and Ordering Guidance

Prior Authorization

Prior Authorization Required

For services described in this policy, precertification/preauthorization is required for all products if the procedure is performed inpatient.

Preauthorization is required for inpatient services described in this policy for all products.

Documentation Required

Documentation and Coding Guidance

Order documentation should indicate symptomatic presentation or a high‑risk condition (for example: inflammatory bowel disease, gastric/intestinal resection, prolonged vegan diet, prolonged use of H2 receptor antagonists or proton pump inhibitors, long‑term metformin use, elderly populations, macrocytic anemia or macrocytosis, neurologic signs). Providers should report services using the most up‑to‑date procedure, revenue, and diagnosis codes and submit an ICD diagnosis code that meets the medical necessity criteria. Failure to meet the medical necessity criteria described in this policy may result in services not being covered.

Report services using current CPT/HCPCS and diagnosis codes.

How to Order and Documentation Needed

Prior Authorization

Ordering: inpatient precertification required; outpatient generally not

Preauthorization is required when the procedure is performed inpatient; outpatient prior authorization generally is not required for Commercial PPO/Indemnity and Medicare HMO and PPO.

Documentation Required

Ordering: document indication; reflex testing may be used

Orders should document the clinical indication or the patient's high‑risk status to justify testing; reflex MMA or holoTC testing may be used based on initial vitamin B12 results.

Include the clinical reason or high‑risk factor on the laboratory order to support medical necessity.
Be prepared to order reflex MMA when serum B12 is normal to low‑normal in high‑risk individuals.

Note

No ordering-provider restrictions specified

The fragment does not specify who is authorized to order holotranscobalamin or vitamin B12 testing.

Services Considered Not Covered

Holotranscobalamin testing is classified as investigational and is therefore listed as NOT COVERED for all indications in this policy.

Routine serum vitamin B12 testing for asymptomatic adults (screening) is not supported by this policy. Testing is recommended for symptomatic patients or those in high‑risk groups, not for average‑risk screening.

The excerpt does not identify any other specific tests or indications that are explicitly excluded from coverage beyond those noted (investigational holotranscobalamin and routine asymptomatic screening).

Key Terms and Definitions

inv-30: MMA — Methylmalonic acid; used to assess for functional B12 deficiency and considered medically necessary when B12 levels are low/borderline or other listed scenarios.

DefinitionMethylmalonic acid (MMA): a small water‑soluble organic acid that increases when B12‑dependent enzymatic activity is impaired

Clinical useUsed to assess for functional vitamin B12 deficiency and as a confirmatory test when serum B12 is low or borderline

Covered indicationsMedically necessary when vitamin B12 levels are low or borderline, in type 2 diabetes with neurologic symptoms on metformin, and for positive newborn screening suggesting organic acidemia

inv-31: Holotranscobalamin — Active B12 (holotranscobalamin) testing is considered investigational for all indications per this policy.

Definition / stanceHolotranscobalamin (active B12) testing is considered INVESTIGATIONAL for all indications per this policy

Testing Frequency and Limits

inv-40: (placeholder) frequency limits — inventory item empty; no explicit frequency limits provided here.

Frequency limitsNo explicit frequency limits provided in this portion of the policy

ImplicationProviders should follow clinical indications and ordering guidance; policy does not specify repeat testing intervals here

DocumentationOrder documentation should indicate symptomatic presentation or high‑risk status to justify testing

inv-41: No explicit frequency limits specified in this portion of the policy.

Policy statementNo explicit frequency limits specified in this portion of the policy

Clinical practiceWhen indicated, reflex MMA testing is appropriate for asymptomatic high‑risk individuals with normal to low‑normal serum B12; policy does not impose numerical frequency caps

Clinical Background

Vitamin B12 deficiency can result from inadequate intake, malabsorption, altered gastrointestinal anatomy or function, certain infections, malignancy affecting absorption, and prolonged use of some medications (for example, long‑term metformin or prolonged acid suppression with PPIs/H2 antagonists). Clinical presentations include neurologic changes, neuropathy, gait abnormalities, cognitive changes, and hematologic findings such as macrocytic anemia; in pediatrics, failure to thrive and developmental delays may occur.

Policy Revision History & Evidence Notes

Prior Authorization

Policy history clarifies coding but not prior‑auth codes

Prior authorization history notes and policy history clarify coding but do not name specific CPT/HCPCS codes that require prior authorization for B12 or holoTC testing.

This fragment does not include explicit authorization or denial triggers. Prior authorization and denial risk statements are referenced elsewhere in the policy; the provided excerpt focuses on coverage stance and clinical indications and cites the endnotes as expert opinion.

OpenPayer

Vitamin B12, Methylmalonic Acid, and Holotranscobalamin Testing

Coverage and Medical Necessity Criteria

Detailed Indications for Testing

Procedure and Diagnosis Codes

Prior Authorization, Documentation, and Ordering Guidance

How to Order and Documentation Needed

Services Considered Not Covered

Key Terms and Definitions

Testing Frequency and Limits

Clinical Background

Policy Revision History & Evidence Notes